As shown in Figure 4A, there exist significant differences in the number of reported viral infection adverse events across cases with different inhibitor groups, with the C5 inhibitor group having markedly more adverse cases than the C3 inhibitor and Factor B inhibitor groups. This evidence concerns the gene C3 and viral infectious disease.